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Abstract
Background: The suboptimal sensitivity of Interferon (IFN)-c-based in-vitro assays, especially in immunocompromised
individuals, emphasizes the need for alternative markers for diagnosing tuberculosis (TB). The objective of this study was to
evaluate whether interferon-inducible protein (IP)-10, monocyte chemotactic protein (MCP)-2 and interleukin (IL)-2 can be
useful biomarkers for evaluating a specific response to RD1 antigens associated to active TB disease in HIV-infected
individuals.
Methodology/Principal Findings: The study was carried out in India, the country with the highest TB burden in the world.
Sixty-six HIV-infected individuals were prospectively enrolled, 28 with active-pulmonary-TB and 38 without. The whole
blood assay based on RD1-selected peptides (experimental test) and QuantiFERON-TB Gold In tube (QFT-IT) was performed.
Plasma was harvested at day-1-post-culture and soluble factors were evaluated by ELISA. The results indicate that by
detecting IP-10, the sensitivity of the experimental test and QFT-antigen (75% and 85.7% respectively) for active TB was
higher compared to the same assays based on IFN-c (42.9% and 60.7% respectively) and was not influenced by the ability to
respond to the mitogen. By detecting IP-10, the specificity of the experimental test and QFT-antigen (57.9% and 13.2%
respectively) for active TB was lower than what was reported for the same assays using IFN-c-detection (78.9% and 68.4%
respectively). On the other side, in vitro IL-2 and MCP-2 responses were not significantly associated with active TB.
Conclusions: HIV infection does not impair RD1-specific response detected by IP-10, while it significantly decreases IFN-c-
mediated responses. At the moment it is unclear whether higher detection is related to higher sensitivity or lower specificity
of the assay. Further studies in high and low TB endemic countries are needed to elucidate this.
Citation: Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, et al. (2010) Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response
in HIV-Infected Persons? PLoS ONE 5(9): e12577. doi:10.1371/journal.pone.0012577
Editor: Madhukar Pai, McGill University, Canada
Received June 28, 2010; Accepted August 6, 2010; Published September 7, 2010
Copyright:  2010 Goletti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by grants from Fondation Me ´rieux and from the Italian Ministry of Health and Ricerca Finalizzata 06.76.1 and 07.103. ML and
ST are employees of Biomerieux. Biomeriueux through their employees’ involvement established the scientific, laboratory and medical network that allowed the
accomplishment of a main project on ‘‘tool box for tuberculosis diagnosis’’ and consequently of the satellite studies. The study described in this manuscript was a
satellite study of the main project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: DG, SC and EG have a European patent N. 1723426 on T-cell assay based on selected RD1 peptides. ML and ST are employees of
Biomerieux. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: delia.goletti@inmi.it
Introduction
Tuberculosis (TB) is the most frequent opportunistic infection in
persons with HIV infection. In 2008, there were an estimated 1.4
million new cases of TB among persons with HIV infection, and
TB accounted for 26% of AIDS-related deaths [1]. Innovative
diagnostic tools for TB, new and enhanced treatment strategies,
and validated markers of treatment efficacy are needed to reduce
the burden of TB-HIV epidemic. This needs to be shown as being
useful in TB-endemic settings [2].
A recent breakthrough in the diagnosis of Mycobacterium
tuberculosis infection has been the development of T-cell-based
Interferon-c Release Assays (IGRAs) that use antigens belonging
to Mycobacterium tuberculosis region of difference (RD1), including
early secreted antigenic target-6 (ESAT-6) and culture filtrate
protein 10 (CFP-10). Two commercial IGRAs, based on
overlapping peptides from CFP-10 and ESAT-6 are now
available. Evidence reviewed elsewhere [3,4] suggests that they
are more specific, correlate better with M. tuberculosis exposure in
low incidence settings and are less affected by bacillus Calmette-
Gue ´rin (BCG) vaccination than the tuberculin skin test (TST).
However, although better than the TST, their accuracy in persons
with HIV is still limited, particularly in ‘‘mitogen- unrespon-
sive’’[5–11] individuals and in those with low CD4
+ T-cell counts.
We developed an in vitro IFN-c immune diagnostic assay for
active TB, the novelty of which consists of the use of multiepitopic
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12577RD1 peptides that are selected by computational analysis [12,13].
The response to these peptides can be detected in individuals with
ongoing M. tuberculosis replication (such as during active TB disease
and/or recent infection) and decreases during TB therapy [14,15].
Sensitivity of the assay to detect active TB is around 70% and thus
needs to be improved [16–18]. Moreover, as for commercial
IGRAs, sensitivity can be reduced in HIV-positive patients [5].
It has been recently shown that the accuracy of IGRAs may be
enhanced by the addition of other M. tuberculosis-specific antigens
[19,20] by improving the incubation step [21–23] or by measuring
biomarkers other than IFN-c. In particular, it has been shown that
IFN-c-inducible protein 10 (IP-10), monocytes chemotactic
protein 2 (MCP-2) and interleukin (IL)-2 may be additional
biomarkers for LTBI detection after RD1-specific stimulation in
both adults [24–28] and children [29]. IP-10 is involved in
trafficking monocytes and activated Th1 cells to inflamed foci
[30]. Serum and pleural fluid IP-10 levels have been evaluated as
biomarkers for diagnosis, prognosis, and monitoring of treatment
efficacy in inflammatory and infectious diseases including TB [31].
M. tuberculosis antigen-dependent IL-2 production has been
demonstrated in patients with active TB [25] and its serum
concentrations (that are elevated in patients with active TB) return
to normal with treatment [32].
TheobjectiveofthisstudywastoevaluatewhetherIP-10,MCP-2
and IL-2 can be useful biomarkers for evaluating a specific response
to RD1 antigens associated to active TB disease in HIV-infected
individuals. To this end, we enrolled HIV-infected patients in India,
thecountrywiththehighestTB burdeninthe world.Indiaaccounts
for one fifth of the global incidence with an estimated 1.9 million
cases annually, 5% of which are HIV-co-infected [33].
Results
Characteristics of the enrolled individuals
We enrolled 66 HIV-infected individuals; 28 of them had active
pulmonary TB (19 microbiologically confirmed and 9 clinically
diagnosed). All patients with active TB were treated as a single
group in the analysis. Among those without active TB, only 3/38
presented symptoms related either to oral candidiasis (2/3) or
chronic liver failure with ascitis (1/3) whereas the others (35/38)
were free of clinical symptoms. CD4
+ T-cell counts and the
demographic and clinical features of the enrolled participants are
described in Table 1.
IP-10 response to RD1 selected peptides was associated
with active TB: quantitative results
The median IP-10 response to the mitogen in those with active
TB (3,986 pg/ml; IQR: 2517-6097) was not significantly different
from what was recorded in individuals without active TB
(4,565 pg/ml; IQR: 2368-7201). On the other hand, the median
response to ESAT-6 selected peptides in patients with active TB
(137.4 pg/ml; IQR: 0-580.7) was significantly different than in
those without active TB (6.22 pg/ml; IQR: 0-187) (p=0.04)
(Figure 1). Similarly, the median response to CFP-10 selected
peptides in those with active TB (268 pg/ml; IQR: 0-2055) was
significantly different (p,0.001) from what was recorded in those
without active TB (100 pg/ml; IQR: 0.00-353). The median
responses to the QFT-antigen in those with active TB (3579 pg/
ml; IQR: 2270-5519) was significantly higher than in those
without active TB (2682 pg/ml; IQR: 868-79-5507) (p=0.04)
(Figure 1). No correlation between the response to IP-10 and
CD4+ T-cell counts was found (data not shown).
No significant differences in MCP-2 and IL-2 responses were
found between those with active TB and those without for all the
stimuli tested (Figure 2A–B).
IP-10 response to RD1 selected peptides and
QFT-antigen: qualitative data
Based on the significant difference found in the quantitative
analysis of the response to IP-10, we performed a receiver-
operator characteristic (ROC) analysis for the IP-10 response to
Table 1. Demographic and clinical characteristics of the HIV-infected individuals enrolled in the study.
No active TB
N. 38
Active TB
N. 28
Median Age (IQR) 31.5 (27.7–40.0) 35.0 (30.5–38.0)
Female gender (%) 14 (36.8) 4 (14.3)
BMI (IQR) 19.8 (18.3–24.5) 20.0 (16.9–22.7)
Pulmonary TB microbiological diagnosis –1 9
Pulmonary TB clinical diagnosis –9
TST median (IQR) 0 (0–0) 5.0 (0–20.0)
TST negative* 30 (78.9) 13 (46.4)
TST positive* 8 (21.1) 12 (42.9)
TST unknown* 0 3 (10.7)
CD4+ T-cell/mm
3 median (IQR)**
N. analyzed
189 (93–455)
28
139 (42–206)
22
CD4+ T-cell/mm
3 (0–100) Number of individuals (%)** 8 (21.1) 9 (32.1)
CD4+ T-cell/mm
3 (101–200) Number of individuals (%)** 7 (18.4) 8 (28.8)
CD4+ T-cell/mm
3 (.200) Number of individuals (%)** 13 (34.2) 5 (17.9)
CD4+ T-cell/mm
3 Unknown 10 (26.3) 6 (21.4)
Footnotes: TB: tuberculosis; IQR: interquartile range; TST: tuberculin skin test; TST*: analyzed in 63/66; CD4
+ T-cell counts**: analyzed in 50/66
individuals.
doi:10.1371/journal.pone.0012577.t001
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potential use in discriminating the different stages of TB. In this
analysis, we used the HIV-uninfected individuals with and without
active TB as comparator groups that were enrolled in parallel, as
reported in a previous study [34]. We constructed the curve using
the highest response value found in response to RD1 selected
peptides, either to CFP-10 or the ESAT-6 peptide pool.
Significant AUC analysis results were obtained (AUC, 0.72;
95% CI, 0.61–0.83, p,0.0003) for IP-10 response to RD1 selected
peptides (Figure 3A). For scoring purposes we chose a cut-off
point to maximize the sum of sensitivity and specificity. We found
that a cut-off point of 350 pg/ml predicted active TB in the HIV-
uninfected individuals with 68.29% sensitivity (95% CI, 51.91%–
81.91%) and 71.11% specificity (95% CI, 55.69%–83.63%).
Significant AUC analysis results were also obtained (AUC, 0.63;
95% CI, 0.51–0.75, p,0.02). for IP-10 response to the TB antigen
of the QFT format (Figure 3B). For scoring purposes we chose a
cut-off point to maximize the sum of sensitivity and specificity. We
found that in HIV-uninfected individuals, a cut-off point of 698 pg/
ml predicted active TB with 90.24% sensitivity (95% CI, 76.87%–
97.28%) and 42.22% specificity (95% CI, 27.66%–57.85%).
By using the cut-off point identified in the ROC analysis, we
found that the sensitivity and specificity of the IP-10-response to
RD1 selected peptides for active TB among the HIV-infected
individuals was 75.0% and 57.9% respectively (Table 2). The
proportion of IP-10-positive responses to RD1 selected peptides
was significantly higher in patients with active TB (21/28, 75.0%)
compared to those without (16/38, 42.1) (p=0.01).
Similarly, by using the cut-off point identified in the ROC
analysis, we found that the sensitivity and specificity of the IP-10-
response to the TB antigen of the QFT format for active TB
among the HIV-infected individuals was 85.7% and 13.2%
respectively (Table 2). The proportion of IP-10-positive responses
to the TB antigen of the QFT format was not significantly higher
in patients with active TB than in those without (p=0.06)
(Table 2).
IFN-c responses to RD1 selected peptides and
QFT-antigen: qualitative data
In vitro IFN-c response to the mitogen was absent in 11/28
(39.2%) of patients with active TB and in 6/38 (15.8%) of
individuals without active TB, and this difference was significant
(p=0.04). Based on a cut-off point identified in the HIV-
uninfected individuals [34], we found that the sensitivity and
specificity of the IFN-c assay based on RD1 selected peptides
among the HIV-infected individuals were 42.9% and 78.9%
respectively if evaluated on the whole population (Table 2). The
sensitivity and the specificity of QFT-IT were 60.7% and 68.4%
respectively.
Comparison of IP-10 and IFN-c responses
There was a significantly higher proportion of positive response
to IP-10 (21/28) than to IFN-c (12/28) after RD1 selected
peptides stimulation (p=0.03) among the HIV-infected individu-
als with active TB. However, no significant difference was found in
those without active TB (16/38 vs. 8/38 respectively) (p=0.08)
Figure 1. IP-10 production in response to RD1 selected peptides and QFT-antigen in HIV-infected individuals. IP-10 release in response
to the RD1 selected peptides and QFT-antigen was evaluated at day 1 in the whole blood of patients with or without active TB. Horizontal lines
indicate the median production. The data are presented as pg/mL. P values are reported, *: p,0.05; **:p,0.005. White circles indicate the individuals
without active TB, black circles indicate the patients with active TB. IP-10 release in response to the RD1 selected peptides and to QFT-antigen was
significantly higher in patients with active TB compared to those without.
doi:10.1371/journal.pone.0012577.g001
IP-10 and IGRA in HIV-TB
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12577Figure 2. IL-2 and MCP-2 production in response to RD1 selected peptides and QFT-antigen in HIV-infected individuals. IL-2 (A) and
MCP-2 (B) release in response to the RD1 selected peptides and QFT-antigen was evaluated at day 1 in the whole blood of patients with or without
active TB. Horizontal lines indicate the median production. White circles indicate the individuals without active TB, black circles indicate the patients
with active TB. No significant differences were found among the different comparisons performed.
doi:10.1371/journal.pone.0012577.g002
IP-10 and IGRA in HIV-TB
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format, there was a higher proportion of positive response to IP-10
(24/28) than to IFN-c (17/28) among those with active TB,
although it was not significant (p=0.06). Interestingly, there was a
significantly higher proportion of positive response to IP-10 (33/
38) than to IFN-c (12/38) among those without active TB
(p=0.0001).
Impact of the response to the mitogen on the score of
the assays based on IFN-c and IP-10: correlation with the
CD4
+ T-cell counts
We evaluated the impact of the ability to respond to the mitogen
on the scoring of IFN-c- or IP-10-based response to either the
RD1 selected peptides or TB antigen of the QFT format. Among
the 11 subjects with active TB classified as ‘‘mitogen-unrespon-
sive’’, only 18.2% (2/11) responded to the assays based on IFN-c
in response to RD1 selected peptides compared to 58.8% (10/17)
of the ‘‘mitogen-responsive’’, and this difference was significant
(p=0.02). Similar results were found for QFT-IT, with 36.4% (4/
11) of those classified as ‘‘mitogen-unresponsive’’ vs. 76.5% (13/
17) of those defined as ‘‘mitogen-responsive’’ and this difference
was close to significance (p=0.052). Differently, regarding the
responses to IP-10 among those classified as ‘‘mitogen-responsive’’,
76.5% (13/17) responded to RD1 selected peptides, similar to the
72.7% (8/11) defined as ‘‘mitogen-unresponsive’’ (p=1). Similar
results were found for the response to the TB-Antigen of the QFT-
IT format, 76.5% (13/17) of those defined as ‘‘mitogen-
responsive’’ vs.100% (11/11) of those defined as ‘‘mitogen-
unresponsive’’ (p=0.13).
Among the patients without active TB, 15.6% (5/32) of the
subjects classified as ‘‘mitogen-responsive’’ responded to the assays
based on IFN-c in response to RD1 selected peptides compared to
50.0% (3/6) of the ‘‘mitogen-unresponsive’’ (p=0.09). Similar
data were obtained in response to QFT-IT, 28.1% (9/32) vs. 50%
(3/6) (p=0.35), respectively. Regarding the responses to IP-10
among those defined as ‘‘mitogen-responsive’’, 37.5% (12/32)
responded to RD1 selected peptides vs. 66.7% (4/6) of those
defined as ‘‘mitogen-unresponsive’’. Similar results were found for
the response to the TB-Antigen of the QFT-IT format, 84.4%
(27/32) vs. 100% (6/6) (p=0.57).
Finally, we evaluated whether there was a difference between
the CD4
+T-cell counts of those defined as ‘‘mitogen- responsive’’
and ‘‘mitogen-unresponsive’’. We found that among all the
patients tested, the CD4
+T-cell counts were significantly lower in
those defined as ‘‘mitogen-unresponsive’’ (median: 41; IQR: 23-
Figure 3. IP-10 release in response to RD1 selected peptides
and TB antigen is associated with active TB. An ROC analysis was
performed among the HIV-uninfected individuals using the active TB
patients and the community controls as comparator groups. A) IP-10
release in response to the RD1 selected peptides is significantly
associated with active TB. B) IP-10 release in response to the QFT-
antigen is associated with active TB.
doi:10.1371/journal.pone.0012577.g003
Table 2. Response to the IP-10-based and IFN-c-based assays in those with or without active TB in HIV-infected individuals.
Active TB No active TB
Stimulus Marker detected Marker detected
IP-10 IFN-c p value IP-10 IFN-c P value
Positive over total
(%)
Positive over total
(%)
RD1-selected peptide test
21/28 (75.0) 12/28 (42.9) 0.028 16/38 (42.1) 8/38 (21.1) 0.08
QFT-IT
24/28 (85.7) 17/28 (60.7) 0.06 33/38 (86.8) 12/38 (31.6) 0.0001
Footnotes: TB: tuberculosis; QFT-IT: QuantiFERON TB Gold In tube; IP: inducible protein; IFN: interferon; RD: region of difference.
doi:10.1371/journal.pone.0012577.t002
IP-10 and IGRA in HIV-TB
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IQR: 95-366) (p=0.03).
Evaluation of test response in relation to the CD4
+ T-cell
count
To evaluate the impact of the CD4
+ T-cell count on the
response to the TB tests in those with HIV infection in detail, we
stratified the CD4
+ T-cell count into 3 categories: i) between 0–
100/ml, ii) 101–200/ml, and iii) above 200/ml( Table 1). Among
those with active TB, there was a significant difference by x
2 for
the trend among the categories of the CD4
+ T-cell counts in the
proportion of responders to the IFN-c based experimental test
(p=0.03), IP-10-based experimental test (p=0.048) and for the
IFN-c-response to the TB antigen of the QFT-IT. Conversely,
no significant difference was found among those without active
TB (data not shown) in any of the comparisons performed
(Figure 4).
Discussion
We are presenting the results of a prospective study conducted
in HIV-infected individuals in India (where TB is highly endemic)
that was designed to investigate if factors other than IFN-c, such as
IP-10, MCP-2 and IL-2 may improve detection of the response to
RD1 antigens for the immunodiagnosis of active TB.
The results of this study demonstrate that besides IFN-c, the IP-
10 response to RD1 selected peptides is associated with active TB
in HIV-infected subjects. There was a significantly higher
proportion of responders to IP-10 than to IFN-c. Response to
RD1 selected peptides detected by either IP-10 or IFN-c was
dependent on the CD4
+ T-cell counts and IFN-c mitogen
response.
Regarding the response to the TB Antigen of the QFT-IT
format, we found that the sensitivity of IP-10 for detecting active
TB was similar to what was reported for the QFT-IT response
(evaluated by definition by IFN-c).However, differently from
QFT-IT, the IP-10-mediated response was not dependent on the
CD4
+ T-cell counts and IFN-c mitogen response. Moreover, there
was a significantly higher proportion of responders to IP-10 than
to QFT-IT in those without active TB, leading to a low specificity
for detecting active disease.
Finally, MCP-2 and IL-2 release was not significantly associated
with active TB in response either to the RD1 selected peptides or
to the TB Antigen of the QFT-IT format.
In this study, we confirmed the data generated in Italy and
Africa; that the in vitro IFN-c response to RD1 selected peptides is
Figure 4. Percentage of positive response to IFN-c and IP-10-based tests in response to RD1 selected peptides and QFT-antigen in
HIV-infected individuals stratified in 3 CD4
+ T-cells categories: i) between 0–100/ml, ii) 101–200/ml, and iii) above 200/ml. P values are
reported, *: p,0.05. Among those with active TB, there was a significant difference by x
2 for the trend between the categories of the CD4
+ T-cell
counts and the proportion of responders to the IFN-c-based experimental test (p=0.032), IP-10-based experimental test (p=0.048) and for the IFN-c-
response to the TB antigen of the QFT-IT.
doi:10.1371/journal.pone.0012577.g004
IP-10 and IGRA in HIV-TB
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IT and/or the response to RD1 intact proteins [5,15]. However,
here we showed that the accuracy (in terms of sensitivity for active
TB detection) of this test is poor, especially in those defined as
‘‘mitogen-unresponsive’’ and in those with low CD4
+ T-cell
counts. In respect to the previous studies, this diversity may be
related to the use of the antiretroviral therapy in the Italian cohort
(36% were receiving antiretrovirals) [5] that may have generated a
higher immunological ability to respond, and/or to the use of the
ELISPOT as a read-out test, which is characterized by a greater
response detection performance than the ELISA [12].
The proportion of responders to QFT-IT in HIV-infected
individuals is similar to what has already been reported in the
literature [6–8,11] and was significantly impaired in those defined
as ‘‘mitogen-unresponsive’’ compared to the ‘‘mitogen-respon-
sive’’, as previously shown [reviewed in 11].
IP-10 detection improves the sensitivity for active TB in the
IFN-c-based tests in response to the RD1 selected peptides and to
QFT-IT, independent of the ability to respond to the mitogen, as
previously shown by others [35]. This higher sensitivity may be
due to the fact that IP-10 is mainly secreted by monocytes/
macrophages [30] while IFN-c and IL-2 are secreted mainly by
CD4
+ T-cells. Hence, IP-10 has the probability of being less
affected by HIV infection and less influenced by low CD4
+ T-cell
counts. However IP-10-based tests, especially those based on QFT
Antigen, show a lower specificity for detecting active TB. This
result may be due to the fact that IP-10 is detected in contacts of
patients with active TB (in both adults [28,34] and children [29],)
and its levels in healthy contacts are not significantly different than
in those with active TB [34]. These results may be important to
underline the high sensitivity of IP-10 in detecting M. tuberculosis
infection compared to IFN-c. In fact, although active TB was
excluded from the HIV-infected individuals of the study
population classified as being without active disease, it was
impossible to rule out contact with M. tuberculosis in a country
like India.
Therefore it is unclear whether the higher proportion of positive
IP-10 results is related to a higher sensitivity in detecting ‘‘infection
per se’’ or to a lower specificity of the assay.
The specificity of the assay based on RD1 selected peptides is
higher when evaluated either by IFN-c or IP-10 detection,
compared to QFT-IT, and this is not unexpected. In fact, QFT-IT
uses a greater variety of epitopes to elicit M. tuberculosis immune
responses by effector memory T-cells and is based on pools of
overlapping peptides spanning the whole length of CFP-10 and
ESAT-6 proteins and an additional peptide from RD11 [3,4].
Conversely, the selective approach of the design of the test based
on RD1 selected peptides reduces the false positive test results
among those without active TB, with a loss of diagnostic sensitivity
for the detection of active TB [12–18]. Whether it is more
acceptable to have false positive test results that may lead to over
treatment, or false negative test results that could potentially lead
to missing cases with active TB to be treated is a matter of debate
and is largely dependent upon the prevalence of M. tuberculosis
infection and the pre-test probability of TB in a community.
According to the literature generated in HIV-uninfected
children [29], in this study on HIV-infected adults we observed
that the stimulation index of IP-10 was lower than that of IFN-c,
despite the higher levels of cytokines produced. This was due to
the higher background level of IP-10 in unstimulated samples
compared to IFN-c (data not shown).
The rate of indeterminate results in our study is 25.7% (17/66),
similar to the rates observed in other studies in which patients with
active TB disease [5–8, and reviewed by 11] and those not
receiving antiretroviral treatment have similar CD4
+ T-cell counts.
It is worthwhile to note that IFN-c response to either RD1 selected
peptides or QFT-IT was detected in a small proportion of patients
defined as mitogen-unresponsive. This may depend on fact that a
better cut-off point for the mitogen should be provided in HIV-
uninfected subjects as suggested by Harada [36] and in HIV-
infected persons, as suggested by Syed Ahamed Kabeer [35]. The
new CDC guidelines for using IGRAs indicate that besides the
mitogen score, the QFT-IT is scored positive based on the specific
response to the antigen [37]. In addition, the IP-10-based assays
are scored positive in the majority of the individuals classified as
‘‘mitogen-unresponsive’’.
It is also important to take into account that we found that the
cut-off point for IP-10 in response to the QFT-antigen in this study
performed in India is very similar (698 pg/ml) to what was
reported by Ruhwald (673 pg/ml) in studies conducted in Europe
with another detection readout [27]. Moreover, the sensitivity of
the assay for active TB diagnosis in the HIV-uninfected individuals
in our study was 90%, close to what was reported by Ruwald [27].
These data are very interesting and may indicate the solidness of
the IP-10-based assay worldwide. Differently, the response of
MCP-2 to the QFT-antigen did not show any diagnostic value.
This data is different than what was previously shown in a
European setting [27] and at the moment, the reason is unclear.
Kabeer at al [35] obtained similar results among the HIV-
infected individuals, however in that study, the cut-off point was
found in a less stringent way than in this study and only few data
regarding the CD4
+ T-cell counts were available.
The study has some limitations. Subjects were selected
according to a certain TB status and comparison between the
in vitro assays and the CD4
+ T-cell counts were made, although
CD4
+ T-cell counts were not performed on the total population.
Nonetheless, although BCG coverage in India is high and we may
expect that the majority of the population studied is BCG-
vaccinated [38], the BCG status of a large number of the
individuals (96.4%) was unknown. However, despite these
limitations, the prospective design of the study, the evaluation of
6 in vitro assays for TB diagnosis (5 experimental and 1
commercial) and the relatively large number of HIV-infected
individuals enrolled to evaluate the performance of the different
immune based tests in clinical practice render the results solid.
In conclusion, we show that HIV infection significantly impairs
the IFN-c response to the mitogen and RD1 tests in those with
active TB, with little impact on IP-10 responses. At the moment it
is unclear whether higher detection of IP-10 is related to higher
sensitivity or to lower specificity of the assay. Further studies are
needed to elucidate it in both high endemic and low endemic TB
countries.
Materials and Methods
Population of patients
Study individuals were prospectively recruited from April, 2007
to March, 2008 in India at: i) Tuberculosis Research Centre,
Chetput, Chennai and ii) P.D.Hinduja National Hospital and
Research Center, Mumbai. The study was approved by the local
ethical committees: the Institutional Ethical Committee of
Tuberculosis Research Centre in Chennai (TRC-IEC No:
2006005) and the Institutional Review Board at Hinduja Hospital,
Mumbai (No: 316 -05-CR). Informed signed consent was required
to participate to the study. Medical information and heparinised
blood were obtained from individuals at enrolment after signing an
informed consent. For this particular study however, we did not
use the results from the Mumbai site because the data were
IP-10 and IGRA in HIV-TB
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+ T-cell counts and detection of
biomarkers different from IFN-c.
The demographic details and information on previous tuber-
culin skin test (TST) results were collected. Individuals with a
previous history of TB, silicosis, end stage renal disease,
leukaemia/lymphoma, who had TST in the past 16 months or
who had received anti-TB therapy or immunosuppressive therapy
for more than two weeks were excluded from the study. Pregnant
and lactating patients were also excluded.
Active TB was defined as microbiologically confirmed if a
sputum smear was positive for acid-fast bacilli (AFB) on
microscopy by Ziehl-Neelsen method and/or M. tuberculosis was
identified in sputum culture in conventional Lowenstein Jensen
(BioMe ´rieux Inc., Marcy I’Etoile, France) and/or in liquid BacT/
ALERT MP medium (BioMe ´rieux Inc., Marcy I’Etoile, France).
Conversely, patients were classified as having ‘‘clinical TB’’ if the
diagnosis was based on clinical and radiologic criteria (after
excluding other diseases) including appropriate response to anti-
tuberculosis therapy.
Subjects classified as ‘‘no TB’’ were free of TB symptoms and
were checked to have a normal chest X-Ray and to be AFB smear
and culture negative. These individuals did not report having had
close contacts with patients with active TB in the past and at this
time of the study. The presence of HIV infection was evaluated by
two ELISA (Retroquic Comb Aids-RS, Span Diagnostics, India
and HIV TRI-DOT, J. Mitra & Co, India) in serum.
Tuberculin Skin Test
TST was performed by intradermally injecting 2 TU (tuberculin
unit) of purified protein derivative (PPD) RT23 (Staten Serum
Institut, Copenhagen, Denmark) by Mantoux method; the
induration was measured by trained professionals between 48–
72 hrs after PPD injection. The cut-off point for TST positivity
was considered as 5 mm for the HIV-infected individuals in
accordance with Indian guidelines [39].
RD1 selected peptides and stimuli used for cell cultures
The selection of Human Leukocytes Antigens (HLA)-class II
restricted epitopes of ESAT-6 and CFP-10 M. tuberculosis proteins
was performed by a quantitative implemented HLA peptide-
binding motif analysis as previously described for ESAT-6 [12,13].
The whole blood test was carried out as previously described [34].
The two centres were provided with RD1 selected peptides from
the same batch, detailed protocol and both received personal
training from INMI’s laboratory staff. Inter-site communication
was present throughout the study to solve any potential problems.
Clinicians were blinded to the laboratory test results and the
laboratory staff was blinded to the status of the patients.
Throughout the test, the assay based on RD1 selected peptides
is also called ‘‘experimental test’’.
IP-10, MCP-2, IL-2 and IFN-c ELISA
The levels of IP-10, MCP-2 and IL-2 were measured in the
plasma of whole blood stimulated with or without the mitogen,
RD1 selected peptides and QFT-Antigen, using Duoset ELISA
Development kits as per the manufacturer’s instructions (R&D
Systems Inc, MN, USA). To detect the chemokines, plasma was
diluted 1:10 as a starting dilution. Further dilutions were
performed when necessary. The levels of IFN-c were evaluated
by a commercial ELISA (CMI, Cellestis Limited, Carnegie,
Victoria, Australia). In general, the data from stimulated whole
blood reported in the text and figures are reported after the
subtraction of the relative unstimulated control, which is either the
whole blood with the same concentration of Dimethyl Sulfoxide
(DMSO) used to dissolve the peptides for the RD1 stimulated
conditions [12,13,34] or the ‘‘nil’’ for the QFT antigen.
Commercially available assays
QFT-IT (Cellestis) was performed and the results were scored as
indicated by the manufacturers. In particular, the results were
scored as indeterminate if the IFN-c response to the mitogen after
subtracting the nil IFN-c response was ,0.5 IU/ml or if the nil
IFN-c response was .8 IU/ml.
Statistical analysis
The median and range of values were calculated. The Mann-
Whitney U test was used to compare continuous variables, and
Chi square was used for categorical variables. Analysis was carried
out with SPSS v 14 for Windows (SPSS Italia SRL, Bologna, Italy).
Receiver-operator characteristic analysis was performed using
Prism 4 software (GraphPad PRISM, version 4.03, La Jolla, CA,
USA).
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